Menu
Menu
THE NEXT GENERATION OF BIOMARKER DISCOVERY
High-Plex proteomics works by translating information on specific protein abundance to information on specific DNA abundance. As such, High-Plex proteomics is succeeding by mimicking transcriptomics. All other existing High-Plex proteomics systems have been built from the bottom-up, by identifying probes for specific proteins one at a time and building an array of such probes.
At NeoVentures Biotechnology Europe we are the only ones to have taken a more powerful approach by working from the top-down. We have developed a platform based on the application of the same 16.8 million aptamers (Aptamarkers) to each sample. We characterize differential binding of these probes to potential biomarkers in biological fluids or tissues through next generation sequencing (NGS) analysis, and validations are performed through qPCR analysis of specific probes.
There are several advantages to our top-down approach:
The Aptamarker Platform operates on the principle of quantifying the amount of individual aptamers within a aptamer library when exposed to a complex mixture of targets. By quantifying the binding of each aptamer, we are able to characterize variation in the amounts of a very large number of targets in blood simultaneously.
The Aptamarker platform is a novel top/down solution to next generation proteomics. While other approaches are built from the bottom up, one probe/protein at a time, our platform applies a library of the same millions of Aptamarkers to every sample. The binding of each of these Aptamarkers to targets is determined by NGS analysis. This approach is both deeper than others, while providing high throughput at a lower cost.
The Aptamarker platform is the next generation in Biomarker discovery. The platform can identify biomarkers and extends characterization beyond the canonical form of proteins to how they exist in biological systems. This means that it is possible to characterize modifications of proteins as a result of folding, complexing (dimers/trimers), isoforms, ion loading, cleavage, and post-translational modifications.
The Aptamarker Platform operates on the principle of quantifying the amount of individual aptamers within a aptamer library when exposed to a complex mixture of targets. By quantifying the binding of each aptamer, we are able to characterize variation in the amounts of a very large number of targets in blood simultaneously.
The Aptamarker platform is a novel top/down solution to next generation proteomics. While other approaches are built from the bottom up, one probe/protein at a time, our platform applies a library of the same millions of Aptamarkers to every sample. The binding of each of these Aptamarkers to targets is determined by NGS analysis. This approach is both deeper than others, while providing high throughput at a lower cost.
The Aptamarker platform is the next generation in Biomarker discovery. The platform can identify biomarkers and extends characterization beyond the canonical form of proteins to how they exist in biological systems. This means that it is possible to characterize modifications of proteins as a result of folding, complexing (dimers/trimers), isoforms, ion loading, cleavage, and post-translational modifications.
Agnostic screening and the capacity to characterize targers of biomarkers.
Exclusion for predisposition to side effects and Inclusion for treatment response.
Prediction of side effect response and translation from animal models
Mapping drug binding sites and developing dynamic test for on/off rates.
Agnostic screening and the capacity to characterize targers of biomarkers.
Exclusion for predisposition to side effects and Inclusion for treatment response.
Prediction of side effect response and translation from animal models
Mapping drug binding sites and developing dynamic test for on/off rates.
Agnostic screening and the capacity to characterize targers of biomarkers.
Exclusion for predisposition to side effects and Inclusion for treatment response.
Prediction of side effect response and translation from animal models
Mapping drug binding sites and developing dynamic test for on/off rates.
The Aptamarker platform has the potential to change the nature of health care. Our vision is to enable personalized medicine to a degree that has not been previously imagined. Personalized health care means personalized diagnosis. We are building a platform that will learn and improve with each additional individual analysed. This will require integration of artificial intelligence and automation. The ultimate goal is to observe the frequencies of everything in blood, to compare this to individual base levels and to determine when something is going wrong immediately as a result of changes. Our platform is the first that makes a future vision like this imaginable and feasible. There is much to do, but overcoming the inevitability of a disease like AD is where we start. We are looking for investors and partners who are committed to creating sustainable improvements to existing health care systems. The basis of such a system will be one that provides individuals with the tools and capacity to manage their own health and wellness.
The Aptamarker platform has the potential to change the nature of health care. Our vision is to enable personalized medicine to a degree that has not been previously imagined. Personalized health care means personalized diagnosis. We are building a platform that will learn and improve with each additional individual analysed. This will require integration of artificial intelligence and automation. The ultimate goal is to observe the frequencies of everything in blood, to compare this to individual base levels and to determine when something is going wrong immediately as a result of changes. Our platform is the first that makes a future vision like this imaginable and feasible. There is much to do, but overcoming the inevitability of a disease like AD is where we start. We are looking for investors and partners who are committed to creating sustainable improvements to existing health care systems. The basis of such a system will be one that provides individuals with the tools and capacity to manage their own health and wellness.
The Aptamarker platform has the potential to change the nature of health care. Our vision is to enable personalized medicine to a degree that has not been previously imagined. Personalized health care means personalized diagnosis. We are building a platform that will learn and improve with each additional individual analysed. This will require integration of artificial intelligence and automation. The ultimate goal is to observe the frequencies of everything in blood, to compare this to individual base levels and to determine when something is going wrong immediately as a result of changes. Our platform is the first that makes a future vision like this imaginable and feasible. There is much to do, but overcoming the inevitability of a disease like AD is where we start. We are looking for investors and partners who are committed to creating sustainable improvements to existing health care systems. The basis of such a system will be one that provides individuals with the tools and capacity to manage their own health and wellness.